Clinical Trial Update: Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describing a phase 1/2 study of bemcentinib plus pacritinib in patients with advanced lung adenocarcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• Bemcentinib (bemcentinib)
• Pacritinib (pacritinib)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Advanced Lung Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING